Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study

OBJECTIVE: To investigate the long-term efficacy and safety of the IL-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK). METHODS: Patients completing the randomized, double-blind, placebo-controlled period of the TAKT (Takayasu arteritis Treated with Tocilizumab) trial were f...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaoka, Yoshikazu, Isobe, Mitsuaki, Tanaka, Yoshiya, Ishii, Tomonori, Ooka, Seido, Niiro, Hiroaki, Tamura, Naoto, Banno, Shogo, Yoshifuji, Hajime, Sakata, Yasushi, Kawakami, Atsushi, Atsumi, Tatsuya, Furuta, Shunsuke, Kohsaka, Hitoshi, Suzuki, Katsuya, Hara, Ryoki, Maejima, Yasuhiro, Tsukamoto, Hiroshi, Takasaki, Yoshinari, Yamashita, Katsuhisa, Okada, Norihiro, Yamakido, Shinji, Takei, Syuji, Yokota, Shumpei, Nishimoto, Norihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449811/
https://www.ncbi.nlm.nih.gov/pubmed/31951279
http://dx.doi.org/10.1093/rheumatology/kez630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449811/
https://www.ncbi.nlm.nih.gov/pubmed/31951279
http://dx.doi.org/10.1093/rheumatology/kez630

Ejemplares similares